1-3 of 3
Daniel E. H. Afar
Close
Sort by
Journal Articles

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Clinical Trials & Observations
Jeffrey A. Zonder, Ann F. Mohrbacher, Seema Singhal, Frits van Rhee, William I. Bensinger, Han Ding, John Fry, Daniel E. H. Afar, Anil K. Singhal
Journal: Blood
Blood (2012) 120 (3): 552–559.
https://doi.org/10.1182/blood-2011-06-360552
Published: 2012
Journal Articles

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cells

Yu-Tzu Tai, Ender Soydan, Weihua Song, Mariateresa Fulciniti, Kihyun Kim, Fangxin Hong, Xian-Feng Li, Peter Burger, Matthew J. Rumizen, Sabikun Nahar, Klaus Podar, Teru Hideshima, Nikhil C. Munshi, Giovanni Tonon, Ruben D. Carrasco, Daniel E. H. Afar, Kenneth C. Anderson
Journal: Blood
Blood (2009) 113 (18): 4309–4318.
https://doi.org/10.1182/blood-2008-10-183772
Published: 2009
Journal Articles

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

Yu-Tzu Tai, Myles Dillon, Weihua Song, Merav Leiba, Xian-Feng Li, Peter Burger, Alfred I. Lee, Klaus Podar, Teru Hideshima, Audie G. Rice, Anne van Abbema, Lynne Jesaitis, Ingrid Caras, Debbie Law, Edie Weller, Wanling Xie, Paul Richardson, Nikhil C. Munshi, Claire Mathiot, Hervé Avet-Loiseau, Daniel E. H. Afar, Kenneth C. Anderson
Journal: Blood
Blood (2008) 112 (4): 1329–1337.
https://doi.org/10.1182/blood-2007-08-107292
Published: 2008
Includes: Supplemental data